SCHEMBL20178542

SCHEMBL20178542

CC(C)Cc1ccc(C(C)C)cc1C#N

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ CYP1A2 P05177 1/20 0.37
▸ CYP3A4 P08684 1/20 0.37
▸ TSHR P16473 1/20 0.37
▸ MAPK1 P28482 1/20 0.37
▸ ADRB2 P07550 1/20 0.37
▸ ADRB1 P08588 1/20 0.37
▸ ADRB3 P13945 1/20 0.37
▸ MCL1 Q07820 1/20 0.36
▸ S1PR1 P21453 1/20 0.36
▸ MAOA P21397 1/20 0.36
▸ MAOB P27338 1/20 0.36
▸ RORC P51449 3/20 0.35
▸ NPC1 O15118 1/20 0.35
▸ ALDH1A1 P00352 1/20 0.35
▸ POLB P06746 1/20 0.35
▸ HPGD P15428 1/20 0.35
▸ RAB9A P51151 1/20 0.35
▸ SMN1; SMN2 Q16637 1/20 0.35
▸ GABRA1 P14867 2/20 0.33
▸ GABRB2 P47870 2/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25786867 0.84 MCL1 (0.40) CYP1A2CYP3A4TSHRMAPK1ADRB2
SCHEMBL19465225 0.82 PDE3B (0.37) CYP1A2CYP3A4TSHRMAPK1ADRB2
SCHEMBL17639914 0.82 CYP1A2 (0.37) CYP1A2CYP3A4TSHRMAPK1ADRB2
SCHEMBL17639917 0.82 ADRB2 (0.40) CYP1A2CYP3A4TSHRMAPK1ADRB2
SCHEMBL22252057 0.81 TACR1 (0.33) CYP1A2CYP3A4TSHRMAPK1ADRB2
SCHEMBL22861975 0.80 S1PR1 (0.39) S1PR1MAOAMAOBRORCALDH1A1
SCHEMBL3027085 0.80 S1PR1 (0.37) TSHRMAPK1S1PR1MAOAMAOB
SCHEMBL24246909 0.79 CYP2A6 (0.34) CYP1A2CYP3A4TSHRMAPK1ADRB2
SCHEMBL21503460 0.79 S1PR1 (0.36) S1PR1MAOAMAOBRORCALDH1A1
SCHEMBL1293961 0.79 AAK1 (0.38) S1PR1MAOAMAOBRORCALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2022026823-A1 CDK19-SELECTIVE INHIBITORS, AND METHODS OF USE THEREOF CHAN ZUCKERBERG BIOHUB, INC. (US) 2022-02-03 — — WO disclosed
US-10597391-B2 Urea-containing isoxazole derivatives as FXR agonists and methods of use thereof ENANTA PHARMACEUTICALS, INC. (US) 2020-03-24 — — US disclosed
US-20180141941-A1 UREA-CONTAINING ISOXAZOLE DERIVATIVES AS FXR AGONISTS AND METHODS OF USE THEREOF ENANTA PHARMACEUTICALS, INC. 2018-05-24 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20180141941-A1 UREA-CONTAINING ISOXAZOLE DERIVATIVES AS FXR AGONISTS AND METHODS OF USE THEREOF NR1H4, FXR1, SLC10A1 CYP1A2 431/4885CYP3A4 305/4885TSHR 320/4885
US-10597391-B2 Urea-containing isoxazole derivatives as FXR agonists and methods of use thereof NR1H4, FXR1, SLC10A1 CYP1A2 431/4885CYP3A4 305/4885TSHR 320/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback